NCT00233779已完成2 期
Sirolimus-Eluting, Heparin-Coated Cobalt Chromium Balloon-Expandable Stent in the Treatment of Patients With de Novo Coronary Artery Lesions in Small Vessels (EVOLUTION)
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 52
- 试验地点
- 2
- 主要终点
- The primary endpoint is in-stent late loss as measured by quantitative coronary angiography (QCA) at 6 months post-procedure.
研究概览
简要总结
The objective of this study is to assess the performance and safety of a sirolimus-eluting, heparin-coated, cobalt chromium balloon-expandable stent (Small Vessel Stent) in patients with de novo native coronary artery lesions in small vessels as compared to historical data from small vessel patients in the RAVEL trial receiving the Sirolimus-eluting Bx VELOCITY™ stent.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •1. The patient must be minimum 18 years of age;
- •2. Diagnosis of angina pectoris as defined by Canadian Cardiovascular Society Classification (CCS I, II, III, IV) OR unstable angina pectoris (Braunwald Classification B\&C, I-II-III) OR patients with documented silent ischemia;
- •3 Treatment of one lesion in a native coronary artery. The treated lesion will be the one with the highest % diameter stenosis by visual estimate. Additional study stents may be used for procedural complications such as dissections. Multivessel treatment is permissible in non-target vessels; however, additional lesions may only be treated with commercial stents. If other non-target vessels are treated with commercial stents during the index procedure, they must be successfully treated prior to the study lesion;
- •4\. The target lesion is \>/=2.0 mm and \50% and \<100% (TIMI I) (visual estimate);
排除标准
- •Patient has experienced a Q-wave or non-Q-wave myocardial infarction with documented total CK>2 times normal within the preceding 24 hours and the CK and CK-MB enzymes remain above normal at the time of treatment;
- •Target lesion is due to in-stent restenosis;
- •Ejection fraction 30%;
- •Totally occluded vessel (TIMI 0 level);
- •Impaired renal function (creatinine > 3.0 mg/dL);
结局指标
主要结局
The primary endpoint is in-stent late loss as measured by quantitative coronary angiography (QCA) at 6 months post-procedure.
时间窗: 6 months post-procedure
次要结局
- In-lesion late loss as measured by QCA at 6 months post-procedure.(6 months post-procedure)
- In-stent and in-lesion minimum lumen diameter (MLD) and percent diameter stenosis (%DS) by QCA post-procedure and at 6 months.(Post-procedure and at 6 months)
- Device success defined as achievement of a final residual diameter stenosis of <50% (by QCA), using the assigned device only. If QCA is not available, the visual estimate of diameter stenosis is used.
- Target Lesion Revascularization (TLR) at six and 12 months.(6 and 12 months)
- Target Vessel Revascularization (TVR) at six and 12 months.(6 and 12 months)
- Composite of Major Adverse Cardiac Events (MACE) defined as death, myocardial infarction (Q wave and non-Q wave), emergent bypass surgery, or repeat target lesion revascularization at 30 days, 6 months and 12 months post-procedure.(30 days, 6 months and 12 months post-procedure)
- Stent Lumen and Stent Obstruction Volume by Intravascular Ultrasound (IVUS) at post procedure and six months follow-up.(post procedure and six months)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
A Study of the SMART Stent in the Treatment SFA Disease.Peripheral Artery DiseaseNCT00232869Cordis Corporation93
已完成
不适用
The All-comers Sirolimus-coated Balloon European RegistryPercutaneous Coronary InterventionAngioplasty, Balloon, CoronaryCoronary Angioplasty, Transluminal BalloonArteriosclerosis, CoronaryNCT03085823Fatebenefratelli and Ophthalmic Hospital2,123
Unknown
不适用
Firebird2 Cobalt-Chromium Alloyed Sirolimus-Eluting Stent Registry TrialCoronary Heart DiseaseNCT00868829Shanghai MicroPort Medical (Group) Co., Ltd.5,000
已完成
2 期
The Initial Double-Blind Drug-Eluting Stent vs Bare-Metal Stent Study.Coronary Artery DiseaseNCT00233805Cordis Corporation220
已完成
1 期
First-in-human Evaluation of the SELUTION DCB, a Novel Sirolimus Coated Balloon in Peripheral ArteriesPatients With Peripheral Artery Disease in the SFA or PANCT02941224M.A. Med Alliance S.A.50